CA Patent

CA2799207C — Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1

Assigned to Curna Inc · Expires 2019-03-26 · 7y expired

What this patent protects

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of …

USPTO Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1.

Drugs covered by this patent

Patent Metadata

Patent number
CA2799207C
Jurisdiction
CA
Classification
—
Expires
2019-03-26
Drug substance claim
No
Drug product claim
No
Assignee
Curna Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.